GLP-1市場：産業動向と世界予測 (～2035年) - 分子タイプ別、使用活性化合物別、GLP-1作動薬タイプ別、GLP-1作動薬別、投与経路別、標的適応症別、地域別、主要医薬品開発企業別、販売予測

GLP-1の市場規模は2024年に493億米ドルとなるとみられ、予測期間の2024年～2035年のCAGRは11.1%と見込まれています。

GLP-1受容体作動薬は、主に2型糖尿病患者の血糖値/グルコースレベルを管理するために利用される薬剤の一種です。さらに、いくつかのGLP-1作動薬は、肥満や関連する心臓病（心血管疾患）の治療にも役立ちます。Lancet誌の調査によると、米国では成人の42.4％が肥満です。さらに、世界保健機関（WHO）によれば、肥満が原因で年間400万人が死亡しています。さらに、世界の成人人口の約5億3,000万人が糖尿病に罹患しており、その98％が2型糖尿病で、糖尿病の有病率は2050年までに約13億人に増加すると予想されており、公衆衛生上の重大な関心事となっています。米国糖尿病協会によると、2021年の死亡原因の第8位が糖尿病であったことは特筆に値します。

近年、ソーシャルメディア、有名人の推薦、消費者への直接広告の影響力の高まりによって、消費者のライフスタイルに顕著な変化が起きています。このため、減量と2型糖尿病治療ソリューションの需要が急増し、この分野の技術革新と市場拡大に拍車がかかるとみられます。2型糖尿病治療薬や体重管理薬に対する需要の増加に対応するため、各社はこのような適応症の治療薬を開発するために様々な取り組みを行っています。その中でもGLP-1作動薬は、継続的な研究開発努力に加え、多くの臨床試験で良好な結果が得られていることから、有望な選択肢として浮上しています。

過去数年の間に、肥満症や2型糖尿病を標的とする多くのGLP-1薬が世界的に承認されました。2024年には、Novo Nordiskが開発したウェゴビーが、肥満または過体重の成人における重篤な心臓疾患の治療薬としてFDAから承認されました。GLP-1受容体作動薬市場としても知られるGLP-1市場は、これらの薬剤の有利な可能性を考慮すると、民間および公的投資家の双方から大きな注目を集めており、予測期間中の市場の大幅な成長につながっています。

当レポートでは、世界のGLP-1市場について調査し、市場の概要とともに、分子タイプ別、使用活性化合物別、GLP-1作動薬タイプ別、GLP-1作動薬別、投与経路別、標的適応症別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 背景

第2章 調査手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

第6章 市場情勢：GLP-1薬

第7章 GLP-1薬：詳細な企業プロファイル

第8章 GLP-1薬：企業プロファイル

第9章 パートナーシップとコラボレーション

第10章 市場への影響分析：促進要因、抑制要因、機会、課題

第11章 世界のGLP-1市場

• 前提と調査手法
• 世界のGLP-1市場、歴史的動向と2035年までの予測

第12章 GLP-1市場、分子タイプ別

第13章 GLP-1市場、使用活性化合物別

第14章 GLP-1市場、GLP-1作動薬タイプ別

第15章 GLP-1市場、GLP-1作動薬別

第16章 GLP-1市場、投与経路別

第17章 GLP-1市場、標的適応症別

第18章 GLP-1市場、地域別

第19章 GLP-1市場、GLP-1薬の販売予測

第20章 GLP-1市場、主要な医薬品開発企業別

第21章 付録1：表形式のデータ

第22章 付録2：企業・団体一覧

List of Tables

• Table 6.1. List of GLP-1 Drugs
• Table 6.2. List of GLP-1 Drug Developers
• Table 7.1. AstraZeneca: Pipeline Portfolio
• Table 7.2. AstraZeneca: Recent Developments and Future Outlook
• Table 7.3. D&D Pharmatech: Pipeline Portfolio
• Table 7.4. D&D Pharmatech: Recent Developments and Future Outlook
• Table 7.5. Eli Lilly: Pipeline Portfolio
• Table 7.6. Eli Lilly: Recent Developments and Future Outlook
• Table 7.7. Novo Nordisk: Pipeline Portfolio
• Table 7.8. Novo Nordisk: Recent Developments and Future Outlook
• Table 7.9. Pfizer: Pipeline Portfolio
• Table 7.10. Pfizer: Recent Developments and Future Outlook
• Table 7.11. Sanofi: Pipeline Portfolio
• Table 7.12. Sanofi: Recent Developments and Future Outlook
• Table 7.13. Tonghua Dongbao Pharmaceutical: Pipeline Portfolio
• Table 7.14. Tonghua Dongbao Pharmaceutical: Recent Developments and Future Outlook
• Table 7.15. Vivani: Pipeline Portfolio
• Table 7.16. Vivani: Recent Developments and Future Outlook
• Table 8.1. Biolingus: Pipeline Portfolio
• Table 8.2. Boehringer Ingelheim: Pipeline Portfolio
• Table 8.3. Gmax Biopharm: Pipeline Portfolio
• Table 8.4. Hanmi Pharmaceutical: Pipeline Portfolio
• Table 8.5. PegBio: Pipeline Portfolio
• Table 8.6. QL Biopharma: Pipeline Portfolio
• Table 8.7. Roche: Pipeline Portfolio
• Table 8.8. Sciwind Biosciences: Pipeline Portfolio
• Table 8.9. Viking Therapeutics: Pipeline Portfolio
• Table 8.10. vTv Therapeutics: Pipeline Portfolio
• Table 9.1. GLP-1 Drug Market: List of Partnerships and Collaborations, Since 2020
• Table 11.1. List of GLP-1 Drugs Forecasted
• Table 21.1. GLP-1 Drugs: Distribution by Status of Development
• Table 21.2. GLP-1 Drugs: Distribution by Type of Molecule
• Table 21.3. GLP-1 Drugs: Distribution by Active Compound Used
• Table 21.4. GLP-1 Drugs: Distribution by Type of Agonist
• Table 21.5. GLP-1 Drugs: Distribution by Route of Administration
• Table 21.6. GLP-1 Drugs: Distribution by Dosing Frequency
• Table 21.7. GLP-1 Drugs: Distribution by Type of Therapy
• Table 21.8. GLP-1 Drugs: Distribution by Target Indication
• Table 21.9. GLP-1 Drugs: Therapeutic Area
• Table 21.10. GLP-1 Drugs Developer: Distribution by Year of Establishment
• Table 21.11. GLP-1 Drugs Developer: Distribution by Company Size
• Table 21.12. GLP-1 Drugs Developer: Distribution by Location of Headquarters
• Table 21.13. GLP-1 Drugs Developer: Distribution by Location of Headquarters (Country) and Status of Development
• Table 21.14. Most Active Developers: Distribution by Number of Drugs
• Table 21.15. AstraZeneca: Annual Revenues, FY 2021-FY 2023 (USD Billion)
• Table 21.16. D&D Pharmatech: Annual Revenues, FY 2021-FY 2023 (KRW Billion)
• Table 21.17. Eli Lilly: Annual Revenues, FY 2021-FY 2023 (USD Billion)
• Table 21.18. Novo Nordisk: Annual Revenues, FY 2021-FY 2023 (DKK Billion)
• Table 21.19. Pfizer: Annual Revenues, FY 2021-FY 2023 (USD Billion)
• Table 21.20. Sanofi: Annual Revenues, FY 2021-FY 2023 (EUR Billion)
• Table 21.21. Tonghua Dongbao Pharmaceutical: Annual Revenues, FY 2021-FY 2023 (RMB Billion)
• Table 21.22. Partnerships and Collaborations: Distribution by Year of Partnership
• Table 21.23. Partnerships and Collaborations: Distribution by Type of Partnership
• Table 21.24. Partnerships and Collaborations: Distribution by Focus Area
• Table 21.25. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
• Table 21.26. Most Active Players: Distribution by Number of Partnerships
• Table 21.27. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Deals
• Table 21.28. Partnerships and Collaborations: Distribution by Local and International Deals
• Table 21.29. Global GLP-1 Market, Historical Trends (2020-2023) (USD Billion)
• Table 21.30. Global GLP-1 Market, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario, (USD Billion)
• Table 21.31. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
• Table 21.32. GLP-1 Market for Biologics, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.33. GLP-1 Market for Small Molecule, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.34. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
• Table 21.35. GLP-1 Market for Dulaglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.36. GLP-1 Market for Liraglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.37. GLP-1 Market for Orforglipron, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.38. GLP-1 Market for Retatrutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.39. GLP-1 Market for Semaglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.40. GLP-1 Market for Survodutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.41. GLP-1 Market for Tirzepatide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.42. GLP-1 Market for Other Active Compounds, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.43. GLP-1 Market: Distribution by Type of GLP-1 Agonist Drug, 2020, 2024 and 2035
• Table 21.44. GLP-1 Market for Long-acting GLP-1 Agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.45. GLP-1 Market for Short-acting GLP-1 Agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.46. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
• Table 21.47. GLP-1 Market for Single-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.48. GLP-1 Market for Dual-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.49. GLP-1 Market for Tri-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.50. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
• Table 21.51. GLP-1 Market for Oral Route, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.52. GLP-1 Market for Parenteral Route, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.53. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
• Table 21.54. GLP-1 Market for Alzheimer's Disease, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.55. GLP-1 Market for Non-alcoholic Steatohepatitis, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.56. GLP-1 Market for Obesity, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.57. GLP-1 Market for Sleep Apnea, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.58. GLP-1 Market for Type 2 Diabetes, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.59. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
• Table 21.60. GLP-1 Market in North America, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.61. GLP-1 Market in US, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.62. GLP-1 Market in Canada, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.63. GLP-1 Market in Europe, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.64. GLP-1 Market in Germany, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.65. GLP-1 Market in UK, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.66. GLP-1 Market in France, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.67. GLP-1 Market in Italy, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.68. GLP-1 Market in Spain, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.69. GLP-1 Market in Asia Pacific, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.70. GLP-1 Market in China, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.71. GLP-1 Market in Japan, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.72. GLP-1 Market in Australia, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.73. GLP-1 Market in South Korea, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.74. GLP-1 Market in Latin America, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.75. GLP-1 Market in Brazil, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.76. GLP-1 Market in Argentina, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.77. Approved GLP-1 Drug, Feisumei (Benaglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.78. Approved GLP-1 Drug, Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.79. Approved GLP-1 Drug, Mounjaro (Tirzepatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.80. Approved GLP-1 Drug, Ozempic (Semaglutide Subcutaneous) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.81. Approved GLP-1 Drug, Rybelsus (Semaglutide Oral) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.82. Approved GLP-1 Drug, Saxenda (Liraglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.83. Approved GLP-1 Drug, Trulicity (Dulaglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.84. Approved GLP-1 Drug, Victoza (Liraglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.85. Approved GLP-1 Drug, Wegovy (Semaglutide Subcutaneous) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.86. Approved GLP-1 Drug, XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.87. Approved GLP-1 Drug, Zepbound (Tirzepatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.88. Phase III GLP-1 Drug, GMA102 / Glutazumab Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.89. Phase III GLP-1 Drug, JY09 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.90. Phase III GLP-1 Drug, LY3298176 / Tirzepatide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.91. Phase III GLP-1 Drug, Mazdutide / LY3305677/ IBI-362 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.92. Phase III GLP-1 Drug, Orforglipron / LY3502970 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.93. Phase III GLP-1 Drug, PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.94. Phase III GLP-1 Drug, Retatrutide / LY3437943 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.95. Phase III GLP-1 Drug, Semaglutide Oral Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.96. Phase III GLP-1 Drug, Semaglutide Subcutaneous Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.97. Phase III GLP-1 Drug, Survodutide / BI 456906 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.98. Phase III GLP-1 Drug, XW003 / Ecnoglutide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.99. Phase III GLP-1 Drug, YN011-isupaglutide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
• Table 21.100. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2020, Conservative, Base and Optimistic Scenario (USD Billion))
• Table 21.101. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2024, Conservative, Base and Optimistic Scenario (USD Billion))
• Table 21.102. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales estimated in 2035, Conservative, Base and Optimistic Scenario (USD Billion))

List of Figures

• Figure 2.1. Research Methodology: Project Methodology
• Figure 2.2. Research Methodology: Forecast Methodology
• Figure 3.1 Lessons Learnt from Past Recessions
• Figure 4.1. Executive Summary: Market Landscape
• Figure 4.2. Executive Summary: Partnerships and Collaborations
• Figure 4.3. Executive Summary: Market Sizing and Opportunity Analysis
• Figure 5.1. Advantage of GLP-1 Drugs
• Figure 5.2. Challenges Associated with GLP-1 Drugs
• Figure 5.3. Mechanisms of Action of GLP-1 Drugs
• Figure 6.1. GLP-1 Drugs: Distribution by Status of Development
• Figure 6.2. GLP-1 Drugs: Distribution by Type of Molecule
• Figure 6.3. GLP-1 Drugs: Distribution by Active Compound Used
• Figure 6.4. GLP-1 Drugs: Distribution by Type of Agonist
• Figure 6.5. GLP-1 Drugs: Distribution by Route of Administration
• Figure 6.6. GLP-1 Drugs: Distribution by Dosing Frequency
• Figure 6.7. GLP-1 Drugs: Distribution by Type of Therapy
• Figure 6.8. GLP-1 Drugs: Distribution by Target Indication
• Figure 6.9. GLP-1 Drugs: Distribution by Therapeutic Area
• Figure 6.10. GLP-1 Drugs Developer: Distribution by Year of Establishment
• Figure 6.11. GLP-1 Drugs Developer: Distribution by Company Size
• Figure 6.12. GLP-1 Drugs Developer: Distribution by Location of Headquarters
• Figure 6.13. GLP-1 Drugs Developer: Distribution by Location of Headquarters (Country) and Status of Development
• Figure 6.14. Most Active Developers: Distribution by Number of Drugs
• Figure 7.1. AstraZeneca: Annual Revenues, FY 2021-FY 2023 (USD Billion)
• Figure 7.2. D&D Pharmatech: Annual Revenues, FY 2021-FY 2023 (Korean Won Billion)
• Figure 7.3. Eli Lilly: Annual Revenues, FY 2021-FY 2023 (USD Billion)
• Figure 7.4. Novo Nordisk: Annual Revenues, FY 2021-FY 2023 (DKK Billion)
• Figure 7.5. Pfizer: Annual Revenues, FY 2021-FY 2023 (USD Billion)
• Figure 7.6. Sanofi: Annual Revenues, FY 2021-FY 2023 (EUR Billion)
• Figure 7.7. Tonghua Dongbao Pharmaceutical: Annual Revenues, FY 2021-FY 2023 (RMB Billion)
• Figure 9.1. Partnerships and Collaborations: Distribution by Year of Partnership
• Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
• Figure 9.3. Partnerships and Collaborations: Distribution by Focus Area
• Figure 9.4. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
• Figure 9.5. Most Active Players: Distribution by Number of Partnerships
• Figure 9.6. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Deals
• Figure 9.7. Partnerships and Collaborations: Distribution by Local and International Deals
• Figure 10.1. GLP-1 Drugs: Market Drivers
• Figure 10.2. GLP-1 Drugs: Market Restraints
• Figure 10.3. GLP-1 Drugs: Market Opportunities
• Figure 10.4. GLP-1 Drugs: Market Challenges
• Figure 11.1. Global GLP-1 Market, Historical Trends and Forecasted Estimates, till 2035
• Figure 11.2. Global GLP-1 Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Billion)
• Figure 11.3. Global GLP-1 Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Billion)
• Figure 12.1. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
• Figure 12.2. GLP-1 Market for Biologics, till 2035 (USD Billion)
• Figure 12.3. GLP-1 Market for Small Molecule, till 2035 (USD Billion)
• Figure 13.1. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
• Figure 13.2. GLP-1 Market for Dulaglutide, till 2035 (USD Billion)
• Figure 13.3. GLP-1 Market for Liraglutide, till 2035 (USD Billion)
• Figure 13.4. GLP-1 Market for Orforglipron, till 2035 (USD Billion)
• Figure 13.5. GLP-1 Market for Retatrutide, till 2035 (USD Billion)
• Figure 13.6. GLP-1 Market for Semaglutide, till 2035 (USD Billion)
• Figure 13.7. GLP-1 Market for Survodutide, till 2035 (USD Billion)
• Figure 13.8. GLP-1 Market for Tirzepatide, till 2035 (USD Billion)
• Figure 13.9. GLP-1 Market for Other Active Compounds, till 2035 (USD Billion)
• Figure 14.1. GLP-1 Market: Distribution by Type of GLP-1 Agonist Drug, 2020, 2024 and 2035
• Figure 14.2. GLP-1 Market for Long-acting GLP-1 Agonist, till 2035 (USD Billion)
• Figure 14.3. GLP-1 Market for Short-acting GLP-1 Agonist, till 2035 (USD Billion)
• Figure 15.1. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
• Figure 15.2. GLP-1 Market for Single-agonist, till 2035 (USD Billion)
• Figure 15.3. GLP-1 Market for Dual-agonist, till 2035 (USD Billion)
• Figure 15.4. GLP-1 Market for Tri-agonist, till 2035 (USD Billion)
• Figure 16.1. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
• Figure 16.2. GLP-1 Market for Oral, till 2035 (USD Billion)
• Figure 16.3. GLP-1 Market for Parenteral, till 2035 (USD Billion)
• Figure 17.1. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
• Figure 17.2. GLP-1 Market for Alzheimer's Disease, till 2035 (USD Billion)
• Figure 17.3. GLP-1 Market for Non-alcoholic Steatohepatitis, till 2035 (USD Billion)
• Figure 17.4. GLP-1 Market for Obesity, till 2035 (USD Billion)
• Figure 17.5. GLP-1 Market for Sleep Apnea, till 2035 (USD Billion)
• Figure 17.6. GLP-1 Market for Type 2 Diabetes, till 2035 (USD Billion)
• Figure 18.1. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
• Figure 18.2. GLP-1 Market in North America, till 2035 (USD Billion)
• Figure 18.3. GLP-1 Market in Europe, till 2035 (USD Billion)
• Figure 18.4. GLP-1 Market in Asia Pacific, till 2035 (USD Billion)
• Figure 18.5. GLP-1 Market in Latin America, till 2035 (USD Billion)
• Figure 19.1. Approved GLP-1 Drug, Feisumei (Benaglutide) Sales Forecast, till 2035 (USD Billion)
• Figure 19.2. Approved GLP-1 Drug, Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast, till 2035 (USD Billion)
• Figure 19.3. Approved GLP-1 Drug, Mounjaro (Tirzepatide) Sales Forecast, till 2035 (USD Billion)
• Figure 19.4. Approved GLP-1 Drug, Ozempic (Semaglutide Subcutaneous) Sales Forecast, till 2035 (US D Billion)
• Figure 19.5. Approved GLP-1 Drug, Rybelsus (Semaglutide Oral) Sales Forecast, till 2035 (USD Billion)
• Figure 19.6. Approved GLP-1 Drug, Saxenda (Liraglutide) Sales Forecast, till 2035 (USD Billion)
• Figure 19.7. Approved GLP-1 Drug, Trulicity (Dulaglutide) Sales Forecast, till 2035 (USD Billion)
• Figure 19.8. Approved GLP-1 Drug, Victoza (Liraglutide) Sales Forecast, till 2035 (USD Billion)
• Figure 19.9. Approved GLP-1 Drug, Wegovy (Semaglutide Subcutaneous) Sales Forecast, till 2035 (USD Billion)
• Figure 19.10. Approved GLP-1 Drug, XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast, till 2035 (USD Billion)
• Figure 19.11. Approved GLP-1 Drug, Zepbound (Tirzepatide) Sales Forecast, till 2035 (USD Billion)
• Figure 19.12. Phase III GLP-1 Drug, GMA102 / Glutazumab Sales Forecast, till 2035 (USD Billion)
• Figure 19.13. Phase III GLP-1 Drug, JY09 Sales Forecast, till 2035 (USD Billion)
• Figure 19.14. Phase III GLP-1 Drug, LY3298176 / Tirzepatide Sales Forecast, till 2035 (USD Billion)
• Figure 19.15. Phase III GLP-1 Drug, Mazdutide / LY3305677/ IBI-362 Sales Forecast, till 2035 (USD Billion)
• Figure 19.16. Phase III GLP-1 Drug, Orforglipron / LY3502970 Sales Forecast, till 2035 (USD Billion)
• Figure 19.17. Phase III GLP-1 Drug, PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast, till 2035 (USD Billion)
• Figure 19.18. Phase III GLP-1 Drug, Retatrutide / LY3437943 Sales Forecast, till 2035 (USD Billion)
• Figure 19.19. Phase III GLP-1 Drug, Semaglutide Oral Sales Forecast, till 2035 (USD Billion)
• Figure 19.20. Phase III GLP-1 Drug, Semaglutide Subcutaneous Sales Forecast, till 2035 (USD Billion)
• Figure 19.21. Phase III GLP-1 Drug, Survodutide / BI 456906 Sales Forecast, till 2035 (USD Billion)
• Figure 19.22. Phase III GLP-1 Drug, XW003 / Ecnoglutide Sales Forecast, till 2035 (USD Billion)
• Figure 19.23. Phase III GLP-1 Drug, YN011-isupaglutide Sales Forecast, till 2035 (USD Billion)
• Figure 20.1. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2020 (USD Billion))
• Figure 20.2. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2024 (USD Billion))
• Figure 20.3. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales estimated in 2035 (USD Billion))

The GLP-1 Market is valued at USD 49.3 billion in 2024 growing at a CAGR of 11.1% during the forecast period 2024-2035.

GLP-1 receptor agonists are a class of medications primarily utilized for managing blood sugar levels / glucose levels in individuals with type 2 diabetes. Further, a few GLP-1 agonists can also help in the treatment of obesity and related heart disease (cardiovascular disease). It is important to mention that, according to a study conducted by Lancet, 42.4% of adult individuals in the US are obese. Moreover, according to the World Health Organization (WHO), 4 million people die annually due to obesity. In addition, nearly 530 million global adult population suffer from diabetes, with 98% of those having type 2 diabetes and prevalence of diabetes is expected to increase to nearly 1.3 billion by 2050, making it a significant public health concern. It is worth mentioning that, according to the American Diabetes Association, diabetes was the eighth leading cause of death in 2021.

In recent years, there has been a notable shift in consumer lifestyles driven by the growing influence of social media, celebrity endorsements and direct-to-consumer advertising. This has led to a surge in the demand for weight loss and type 2 diabetes treatment solutions, which is likely to spur innovation and market expansion in this domain. In order to address the increasing demand for type 2 diabetes and body weight management drugs, various initiatives have been undertaken by players to develop drugs for treatment of such indications; of these, GLP-1 agonist drugs have emerged as promising option driven by the significant number of positive clinical trial results, along with continuous research and development efforts.

Over the past few years, a number of GLP-1 drugs targeting obesity and type 2 diabetes have received regulatory approvals globally. In 2024, the FDA approved Wegovy, developed by Novo Nordisk, for the treatment of serious heart problems in adults with obesity or overweight. Given the lucrative potential of these drugs, the GLP-1 market, also known as GLP-1 receptor agonist market, has gained significant attention of both private and public investors leading to the substantial market growth during the forecast period.

Key Market Segments

Type of Molecule

• Biologics
• Small Molecules

Active Compound Used

• Dulaglutide
• Liraglutide
• Orforglipron
• Retatrutide
• Semaglutide
• Survodutide
• Tirzepatide
• Other Active Compounds

Type of GLP-1 Agonist Drugs

• Long-acting GLP-1 Agonist
• Short-acting GLP-1 Agonist

Type of Agonist

• Single agonist
• Dual agonist
• Tri-agonist

Route of Administration

• Oral
• Parenteral

Target Indication

• Alzheimer's Disease
• Non-Alcoholic Steatohepatitis
• Obesity
• Sleep Apnea
• Type 2 Diabetes

Key Geographical Regions

• North America
• Europe
• Asia Pacific
• Latin America

Leading Drug Developers

• Boehringer Ingelheim
• Eli Lilly
• Novo Nordisk
• Other Developers

Research Coverage:

• A detailed assessment of the overall market landscape of GLP-1 drugs, along with information on several relevant parameters, such as stage of development (Marketed, Clinical (Phase III, Phase II, Phase I), IND-Enabling and Discovery / Preclinical), type of molecule (biologics and small molecules), active compound used (ecnoglutide, efocipegtrutide, exenatide, froniglutide, isupaglutide, liraglutide, lixisenatide, semaglutide, tirzepatide, utreglutide and other active compounds), GLP-1 agonist (single-agonist, dual-agonist and tri-agonist), route of administration (intraarticular, oral, subcutaneous and sublingual), dosing frequency (single dose, once monthly, once weekly, twice weekly, once daily and twice daily), type of therapy (combination therapy and monotherapy), target indication (Alzheimer's disease, congenital hyperinsulinism, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis (NASH drugs), obesity, obstructive apnea syndrome, Parkinson's disease, sarcopenia, type 2 diabetes and other target indication) and therapeutic area (genetic disorders, inflammatory disorders, metabolic disorders, neurological disorders, neuromuscular disorders, respiratory disorder and other therapeutic areas). In addition, the chapter provides a detailed list of developers engaged in developing GLP-1 drugs, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters (North America, Europe and Asia-Pacific and Rest of the world) of the players involved in this market space.
• Elaborate profiles of prominent players developing GLP-1 drugs (shortlisted based on the number of drugs in its pipeline). Each profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and leadership team), financial information, drug portfolio, recent developments and an informed future outlook.
• A detailed analysis of the partnerships inked between stakeholders in the GLP-1 industry, based on several parameters, such as year of partnership, type of partnership, type of molecule, type of partner and most active players (in terms of the number of partnerships signed) and regional distribution of partnership activity in this domain, since 2020
• An in-depth analysis of the factors that can impact the growth of GLP-1 companies. It also features identification and analysis of key GLP-1 market drivers, potential restraints, emerging opportunities, and existing challenges.
• A detailed GLP-1 receptor agonist market forecast analysis in order to estimate the existing market size and future opportunity for GLP-1 companies over the next decade. Based on multiple parameters, such as likely adoption trends, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within the global GLP-1 receptor agonist market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
• Detailed projection of the current and future opportunity within the GLP-1 market across different types of molecules, namely biologics and small molecules.
• Detailed projection of the current and future opportunity within the GLP-1 receptor agonist market across different active compound used, namely dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide and other active compounds.
• Detailed projection of the current and future opportunity within the GLP-1 industry across different types of GLP-1 agonist drug, namely long-acting GLP-1 agonist and short-acting GLP-1 agonist.
• Detailed projection of the current and future opportunity within the GLP-1 industry across different types of agonists, namely single-agonist, dual-agonist and tri-agonist.
• Detailed projection of the current and future opportunity within the GLP-1 receptor agonist market across different routes of administration, namely oral and parenteral.
• Detailed projection of the current and future opportunity within the GLP-1 market across different target indication, namely Alzheimer's disease, non-alcoholic steatohepatitis, obesity, sleep apnea, type 2 diabetes.
• Detailed projection of the current and future opportunity within the GLP-1 industry across different key geographical regions, namely North America, Europe, Asia-Pacific and Latin America.
• Detailed projections of the current and future GLP-1 market for the sales of forecasted drugs.
• Detailed projections of the current and future revenues from the sales of drugs developed by the leading players, namely Boehringer Ingelheim, Eli Lilly, Novo Nordisk and other players.

Key Benefits of Buying this Report

• The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
• Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
• The report provides stakeholders with a pulse on the GLP-1 Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

• AstraZeneca
• Biolingus
• Boehringer Ingelheim
• D&D Pharmatech
• Eli Lilly
• Gmax Biopharm
• Hanmi Pharmaceutical
• Innogen
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharma
• Roche
• Sanofi
• Sciwind Biosciences
• Tonghua Dongbao Pharmaceutical
• Viking Therapeutics
• Vivani
• vTv Therapeutic

TABLE OF CONTENTS

1 BACKGROUND

• 1.1. Context
• 1.2. Project Objectives

2 RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage and Foreign Exchange Rate
    • 3.2.2.1. Major Currencies Affecting the Market
    • 3.2.2.2. Factors affecting Currency Fluctuations and Foreign Exchange Rates
    • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on Market
    • 3.2.2.4. Strategies For Mitigating Foreign Exchange Risk
  • 3.2.3. Trade Policies
    • 3.2.3.1. Impact of Trade Barriers on the Market
    • 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4 EXECUTIVE SUMMARY

5 INTRODUCTION

• 5.1. Overview of the GLP-1 Drug
  • 5.1.1. Challenges Associated with GLP-1 Drugs
  • 5.1.2. Mechanism of Action of GLP-1 Drugs
• 5.2. Important Facts in GLP-1 Domain
• 5.3. Future Perspectives

6 MARKET LANDSCAPE: GLP-1 DRUGS

• 6.1. GLP-1 Drugs: Market Landscape
  • 6.1.1. Analysis by Status of Development
  • 6.1.2. Analysis by Type of Molecule
  • 6.1.3. Analysis by Active Compound Used
  • 6.1.4. Analysis by Type of Agonist
  • 6.1.5. Analysis by Route of Administration
  • 6.1.6. Analysis by Dosing Frequency
  • 6.1.7. Analysis by Type of Therapy
  • 6.1.8. Analysis by Target Indication
  • 6.1.9. Analysis by Therapeutic Area
• 6.2. GLP-1 Drugs: Developer Landscape
  • 6.2.1. Analysis by Year of Establishment
  • 6.2.2. Analysis by Company Size
  • 6.2.3. Analysis by Location of Headquarters
  • 6.2.4. Analysis by Location of Headquarters (Country) and Status of Development
  • 6.2.5. Most Active Developers: Analysis by Number of Therapies

7 GLP-1 DRUGS: DETAILED COMPANY PROFILES

• 7.1. Chapter Overview
  • 7.1.1. AstraZeneca
    • 7.1.1.1. Company Overview
    • 7.1.1.2. Pipeline Portfolio
    • 7.1.1.3. Financial Details
    • 7.1.1.4. Recent Developments and Future Outlook
  • 7.1.2. D&D Pharmatech
    • 7.1.2.1. Company Overview
    • 7.1.2.2. Pipeline Portfolio
    • 7.1.2.3. Financial Details
    • 7.1.2.4. Recent Developments and Future Outlook
  • 7.1.3. Eli Lilly
    • 7.1.3.1. Company Overview
    • 7.1.3.2. Pipeline Portfolio
    • 7.1.3.3. Financial Details
    • 7.1.3.4. Recent Developments and Future Outlook
  • 7.1.4. Novo Nordisk
    • 7.1.4.1. Company Overview
    • 7.1.4.2. Pipeline Portfolio
    • 7.1.4.3. Financial Details
    • 7.1.4.4. Recent Developments and Future Outlook
  • 7.1.5. Pfizer
    • 7.1.5.1. Company Overview
    • 7.1.5.2. Pipeline Portfolio
    • 7.1.5.3. Financial Details
    • 7.1.5.4. Recent Developments and Future Outlook
  • 7.1.6. Sanofi
    • 7.1.6.1. Company Overview
    • 7.1.6.2. Pipeline Portfolio
    • 7.1.6.3. Financial Details
    • 7.1.6.4. Recent Developments and Future Outlook
  • 7.1.7. Tonghua Dongbao Pharmaceutical
    • 7.1.7.1. Company Overview
    • 7.1.7.2. Pipeline Portfolio
    • 7.1.7.3. Financial Details
    • 7.1.7.4. Recent Developments and Future Outlook
  • 7.1.8. Vivani
    • 7.1.8.1. Company Overview
    • 7.1.8.2. Pipeline Portfolio
    • 7.1.8.3. Financial Details
    • 7.2.8.4. Recent Developments and Future Outlook

8 GLP-1 DRUGS: BRIEF COMPANY PROFILES

• 8.1. Chapter Overview
  • 8.1.1. Biolingus
    • 8.1.1.1. Company Overview
    • 8.1.1.2. Pipeline Portfolio
  • 8.1.2. Boehringer Ingelheim
    • 8.1.2.1. Company Overview
    • 8.1.2.2. Pipeline Portfolio
  • 8.1.3. Gmax Biopharm
    • 8.1.3.1. Company Overview
    • 8.1.3.2. Pipeline Portfolio
  • 8.1.4. Hanmi Pharmaceutical
    • 8.1.4.1. Company Overview
    • 8.1.4.2. Pipeline Portfolio
  • 8.1.5. Innogen
    • 8.1.5.1. Company Overview
    • 8.1.5.2. Pipeline Portfolio
  • 8.1.6. PegBio
    • 8.1.6.1. Company Overview
    • 8.1.6.2. Pipeline Portfolio
  • 8.1.7. QL Biopharma
    • 8.1.7.1. Company Overview
    • 8.1.7.2. Pipeline Portfolio
  • 8.1.8. Roche
    • 8.1.8.1. Company Overview
    • 8.1.8.2. Pipeline Portfolio
  • 8.1.9. Sciwind Biosciences
    • 8.1.9.1. Company Overview
    • 8.1.9.2. Pipeline Portfolio
  • 8.1.10. Viking Therapeutics
    • 8.1.10.1. Company Overview
    • 8.1.10.2. Pipeline Portfolio
  • 8.1.11. vTv Therapeutics
    • 8.1.11.1. Company Overview
    • 8.1.11.2. Pipeline Portfolio

9 PARTNERSHIPS AND COLLABORATIONS

• 9.1. Chapter Overview
• 9.2. Partnership Models
• 9.3. GLP-1 Market: Partnerships and Collaborations
  • 9.3.1. Analysis by Year of Partnership
  • 9.3.2. Analysis by Type of Partnership
  • 9.3.3. Analysis by Focus Area
  • 9.3.4. Analysis by Year and Type of Partnership
  • 9.3.5. Most Active Players: Analysis by Number of Partnerships
  • 9.3.6. Analysis by Geography
    • 9.3.6.1. Intercontinental and Intracontinental Deals
    • 9.3.6.2. Local and International Deals

10 MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 10.1. Chapter Overview
• 10.2. Market Drivers
• 10.3. Market Restraints
• 10.4. Market Opportunities
• 10.5. Market Challenges
• 10.6. Conclusion

11 GLOBAL GLP-1 MARKET

• 11.1. Assumptions and Methodology
• 11.2. Global GLP-1 Market, Historical Trends and Forecasted Estimates, till 2035
  • 11.2.1. Scenario Analysis
    • 11.2.1.1. Conservative Scenario
    • 11.2.1.2. Optimistic Scenario
  • 11.2.2. Key Market Segmentations

12 GLP-1 MARKET, BY TYPE OF MOLECULE

• 12.1. Assumptions and Methodology
• 12.2. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
  • 12.2.1. GLP-1 Market for Biologics, till 2035
  • 12.2.2. GLP-1 Market for Small Molecules, till 2035
• 12.3. Data Triangulation and Validation

13 GLP-1 MARKET, BY ACTIVE COMPOUND USED

• 13.1. Assumptions and Methodology
• 13.2. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
  • 13.2.1. GLP-1 Market for Dulaglutide, till 2035
  • 13.2.2. GLP-1 Market for Liraglutide, till 2035
  • 13.2.3. GLP-1 Market for Orforglipron, till 2035
  • 13.2.4. GLP-1 Market for Retatrutide, till 2035
  • 13.2.5. GLP-1 Market for Semaglutide, till 2035
  • 13.2.6. GLP-1 Market for Survodutide, till 2035
  • 13.2.7. GLP-1 Market for Tirzepatide, till 2035
  • 13.2.8. GLP-1 Market for Other Active Compounds, till 2035
• 13.3 Data Triangulation and Validation

14 GLP-1 MARKET, BY TYPE OF GLP-1 AGONIST DURGS

• 14.1. Assumptions and Methodology
• 14.2. GLP-1 Market: Distribution by Type of GLP-1 Agonist Drugs, 2020, 2024 and 2035
  • 14.2.1. GLP-1 Market for Long-acting GLP-1 Agonist, till 2035
  • 14.2.2. GLP-1 Market for Short-acting GLP-1 Agonist, till 2035
• 14.3. Data Triangulation and Validation

15 GLP-1 MARKET, BY GLP-1 AGONIST

• 15.1. Assumptions and Methodology
• 15.2. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
  • 15.2.1. GLP-1 Market for Single-agonist, till 2035
  • 15.2.2. GLP-1 Market for Dual-agonist, till 2035
  • 15.2.3. GLP-1 Market for Tri-agonist, till 2035
• 15.3. Data Triangulation and Validation

16 GLP-1 MARKET, BY ROUTE OF ADMINISTRATION

• 16.1. Assumptions and Methodology
• 16.2. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
  • 16.2.1. GLP-1 Market for Oral Route, till 2035
  • 16.2.2. GLP-1 Market for Parenteral Route, till 2035
• 16.3. Data Triangulation and Validation

17 GLP-1 MARKET, BY TARGET INDICATION

• 17.1. Assumptions and Methodology
• 17.2. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
  • 17.2.1. GLP-1 Market for Alzheimer's Disease, till 2035
  • 17.2.2. GLP-1 Market for Non-Alcoholic Steatohepatitis, till 2035
  • 17.2.3. GLP-1 Market for Obesity, till 2035
  • 17.2.4. GLP-1 Market for Sleep Apnea, till 2035
  • 17.2.5. GLP-1 Market for Type 2 Diabetes, till 2035
• 17.3. Data Triangulation and Validation

18 GLP-1 MARKET, BY GEOGRAPHY

• 18.1. Assumptions and Methodology
• 18.2. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
  • 18.2.1. GLP-1 Market in North America, till 2035
  • 18.2.2. GLP-1 Market in Europe, till 2035
  • 18.2.3. GLP-1 Market in Asia-Pacific, till 2035
  • 18.2.4. GLP-1 Market in Latin America, till 2035
• 18.3. Data Triangulation and Validation

19 GLP-1 MARKET, SALES FORECAST OF GLP-1 DRUGS

• 19.1. Chapter Overview
• 19.2. Approved GLP-1 Drugs: Sales Forecast
  • 19.2.1. Feisumei (Benaglutide) Sales Forecast
  • 19.2.2. Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast
  • 19.2.3. Mounjaro (Tirzepatide) Sales Forecast
  • 19.2.4. Ozempic (Semaglutide Subcutaneous) Sales Forecast
  • 19.2.5. Rybelsus (Semaglutide Oral) Sales Forecast
  • 19.2.6. Saxenda (Liraglutide) Sales Forecast
  • 19.2.7. Trulicity (Dulaglutide) Sales Forecast
  • 19.2.8. Victoza (Liraglutide) Sales Forecast
  • 19.2.9. Wegovy (Semaglutide Subcutaneous) Sales Forecast
  • 19.2.10. XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast
  • 19.2.11. Zepbound (Tirzepatide) Sales Forecast
• 19.3. Phase III GLP-1 Drugs: Sales Forecast
  • 19.3.1. GMA102 / Glutazumab Sales Forecast
  • 19.3.2. JY09 Sales Forecast
  • 19.3.3. LY3298176 / Tirzepatide Sales Forecast
  • 19.3.4. Mazdutide / LY3305677/ IBI-362 Sales Forecast
  • 19.3.5. Orforglipron / LY3502970 Sales Forecast
  • 19.3.6. PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast
  • 19.3.7. Retatrutide / LY3437943 Sales Forecast
  • 19.3.8. Semaglutide Oral Sales Forecast
  • 19.3.9. Semaglutide Subcutaneous Sales Forecast
  • 19.3.10. Survodutide / BI 456906 Sales Forecast
  • 19.3.11. XW003 / Ecnoglutide Sales Forecast
  • 19.3.12. YN011-isupaglutide Sales Forecast

20 GLP-1 MARKET, BY LEADING DRUG DEVELOPERS

• 20.1. Chapter Overview
• 20.2. GLP-1 Market: Distribution by Leading Drug Developers, 2020 (USD Million)
• 20.3. GLP-1 Market: Distribution by Leading Drug Developers, 2024 (USD Million)
• 20.4. GLP-1 Market: Distribution by Leading Drug Developers, 2035 (USD Million)

21 APPENDIX 1: TABULATED DATA

22 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS